Italia markets closed

T2 Biosystems, Inc. (0A57.L)

LSE - LSE Prezzo differito. Valuta in USD.
Aggiungi a watchlist
0,0969+0,0053 (+5,79%)
Alla chiusura: 03:47PM BST

T2 Biosystems, Inc.

101 Hartwell Avenue
Lexington, MA 02421
United States
781 761 4646

Impiegati a tempo pieno182

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Mr. John J. Sperzel III, B.Sc.Pres, CEO & Chairman1,03MN/D1963
Mr. Alec J. BarclaySr. VP & COO544,43kN/D1980
Mr. Michael Terrence Gibbs Esq.Sr. VP & Gen. Counsel527,21kN/D1971
Mr. John M. Sprague CPAChief Financial OfficerN/DN/D1958
Ms. Kelley J. MorganChief People OfficerN/DN/D1976
Dr. Aparna Jha Ahuja M.D.Chief Medical Officer & Chairman of Scientific Advisory BoardN/DN/D1967
Mr. Brett A. GiffinChief Commercial OfficerN/DN/D1959
Dr. Roger Smith Ph.D.Sr. VP of Science R&DN/DN/D1965
Gli importi risalgono al giorno 31 dicembre 2021 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.


T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument that runs various diagnostic tests from patient samples; T2Candida, a direct-from-blood test that identifies blood stream infections that causes sepsis and candidemia; T2Bacteria, a direct-from-blood test, which detects bacterial pathogens associated with sepsis; T2Resistance to identify carbapenem resistance genes; and T2SARS-CoV-2 panel to detect SARS-CoV-2 virus. In addition, it is developing T2Biothreat for detection of biothreat pathogens; comprehensive sepsis panel to detect bloodstream infections caused by bacterial and Candida species, and antibiotic resistant markers; T2Cauris to provide direct detection of the emerging superbug Candida auris in patient skin, patient blood, and hospital environmental samples; and T2Lyme, a direct-from-blood test panel designed to run on the T2Dx Instrument to identify the bacteria that cause Lyme disease. The company has collaboration agreements with Canon U.S. Life Sciences, Inc. to develop a diagnostic test panel to detect Lyme disease. T2 Biosystems, Inc. was incorporated in 2006 and is headquartered in Lexington, Massachusetts.

Governance aziendale

L'ISS Governance QualityScore di T2 Biosystems, Inc. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.